-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
ICML Conference 2021 The 16th International Conference on Malignant Lymphoma (ICML) will be held online from June 18 to June 22, 2021
.
As the most influential conference in the field of lymphoma in the world, the ICML conference will introduce and discuss the latest basic, translational, and clinical data on lymphoma
.
With the rapid development of clinical research in China, China is also playing an increasingly important role in the field of hematology in the world.
In the context of the new crown epidemic, it has provided the world's hematologists with valuable patient management experience
.
Which Chinese experts' research results have been brilliantly unveiled at this year's ICML conference? Let us take a look
.
2021 ICML Chinese Expert Oral Report Summary 01 Abstract Number: 026 Title: Genetic Subtype Guided Rituximab-based Immunochemotherapy Improves Outcome in Newly Diagnosed Diffuse Large B-cell Lymphoma: First Report of a Randomized Phase 2 Study.
Author: M.
Zhang Unit: Shanghai Ruijin Hospital Affiliated to Jiaotong University School of Medicine 02 Abstract Number: 052 Title: ESA versus MESA with sandwiched radiotherapy in patients with early-stage natural killer/T-cell lymphoma: a multicentre, randomised, phase 3, non-inferiority trial.
Author: H .
-J.
Zhong Unit: Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine 2021 ICML China Expert Poster Presentation Summary 01 Abstract Number: 131 Title: Updated Efficacy and Safety Results of Orelabrutinib in the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Cell Leukemia Author: W.
Xu Unit: The First Affiliated Hospital of Nanjing Medical University 02 Abstract Number: 159 Title: Phase Ib/II study of Lenalidomide, Rituximab, High-dose Methotrexate (R2-MTX) regimen, followed by lenalidomide maintenance in Newly Diagnosed Primary CNS Lymphoma.
Author: Y.
Zhang Unit: Peking Union Medical College Hospital 03 Abstract Number: 163 Title: Lenalidomide and rituximab regimen combined with intravitreal methotrexate followed by lenalidomide maintenance for primary vitreoretinal lymphoma: a prospective phase II study.
Author: Y.
Zhang Unit: Peking Union Medical College Hospital 04 Abstract Number: 192 Title: Camrelizumab Combined with GEMOX in Patients with Relapsed or Refractory Hodgkin Lymphoma.
Author: Y.
Xie Unit: Peking University Cancer Hospital 05 Abstract Number: 215 Title: Sintilimab plus Chidamide for Relapsed/Refractory (r/r) Extranodal NK/T Cell Lymphoma (ENKTL): A Prospective, Multicenter, Single-Arm, Phase Ib/II Trial (SCENT).
Author: H.
Huang Unit: Sun Yat-sen University Cancer Center 06 Abstract Number: 216 Title: A Phase Ib study of an oral PI3Kδ inhibitor Linperlisib in patients with relapsed or refractory peripheral T cell lymphoma.
Author: L.
Qiu Unit: Hematology Hospital of Chinese Academy of Medical Sciences 07 Abstract Number: 224 Title: Circulating tumor DNA by high-throughput sequencing of T cell receptor monitored treatment response and predicted treatment failure in T cell lymphomas.
Author: W.
Wang Unit: Peking Union Medical College Hospital 08 Abstract Number: 234 Title: Glycoprotein PTGDS Acts as a Potential Target in Diffuse Large B-Cell Lymphoma by regulating MYH9-Wnt-β-catenin/STAT3 axis.
Author: S.
Hu Unit: Shandong Provincial Hospital 09 Abstract Number: 256 Title: A Phase II Study of Anti-PD-1 Sintilimab in Combination With Chidamide and Azacitidine in Refractory and Relapsed Peripheral T-cell Lymphoma.
Author: Z.
Ying Unit: Peking University Cancer Hospital 10 Abstract Number: 269 Title: A single- arm, open-label, pilot trial of Autologous CD7-CAR-T Cells for CD7 Positive Relapsed and Refractory T-lymphoblastic leukemia/lymphoma.
Author: M.
Zhang Unit: The First Affiliated Hospital of Zhengzhou University 11 Abstract Number: 282 Title: Burden of lymphoma in China, 1990−2019: an analysis of Global Burden of Diseases, Injuries, and Risk Factors Study 2019.
Author: W.
Unit Liu: If there is any omission from Peking University Cancer Hospital, please leave us a message
.
.
As the most influential conference in the field of lymphoma in the world, the ICML conference will introduce and discuss the latest basic, translational, and clinical data on lymphoma
.
With the rapid development of clinical research in China, China is also playing an increasingly important role in the field of hematology in the world.
In the context of the new crown epidemic, it has provided the world's hematologists with valuable patient management experience
.
Which Chinese experts' research results have been brilliantly unveiled at this year's ICML conference? Let us take a look
.
2021 ICML Chinese Expert Oral Report Summary 01 Abstract Number: 026 Title: Genetic Subtype Guided Rituximab-based Immunochemotherapy Improves Outcome in Newly Diagnosed Diffuse Large B-cell Lymphoma: First Report of a Randomized Phase 2 Study.
Author: M.
Zhang Unit: Shanghai Ruijin Hospital Affiliated to Jiaotong University School of Medicine 02 Abstract Number: 052 Title: ESA versus MESA with sandwiched radiotherapy in patients with early-stage natural killer/T-cell lymphoma: a multicentre, randomised, phase 3, non-inferiority trial.
Author: H .
-J.
Zhong Unit: Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine 2021 ICML China Expert Poster Presentation Summary 01 Abstract Number: 131 Title: Updated Efficacy and Safety Results of Orelabrutinib in the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Cell Leukemia Author: W.
Xu Unit: The First Affiliated Hospital of Nanjing Medical University 02 Abstract Number: 159 Title: Phase Ib/II study of Lenalidomide, Rituximab, High-dose Methotrexate (R2-MTX) regimen, followed by lenalidomide maintenance in Newly Diagnosed Primary CNS Lymphoma.
Author: Y.
Zhang Unit: Peking Union Medical College Hospital 03 Abstract Number: 163 Title: Lenalidomide and rituximab regimen combined with intravitreal methotrexate followed by lenalidomide maintenance for primary vitreoretinal lymphoma: a prospective phase II study.
Author: Y.
Zhang Unit: Peking Union Medical College Hospital 04 Abstract Number: 192 Title: Camrelizumab Combined with GEMOX in Patients with Relapsed or Refractory Hodgkin Lymphoma.
Author: Y.
Xie Unit: Peking University Cancer Hospital 05 Abstract Number: 215 Title: Sintilimab plus Chidamide for Relapsed/Refractory (r/r) Extranodal NK/T Cell Lymphoma (ENKTL): A Prospective, Multicenter, Single-Arm, Phase Ib/II Trial (SCENT).
Author: H.
Huang Unit: Sun Yat-sen University Cancer Center 06 Abstract Number: 216 Title: A Phase Ib study of an oral PI3Kδ inhibitor Linperlisib in patients with relapsed or refractory peripheral T cell lymphoma.
Author: L.
Qiu Unit: Hematology Hospital of Chinese Academy of Medical Sciences 07 Abstract Number: 224 Title: Circulating tumor DNA by high-throughput sequencing of T cell receptor monitored treatment response and predicted treatment failure in T cell lymphomas.
Author: W.
Wang Unit: Peking Union Medical College Hospital 08 Abstract Number: 234 Title: Glycoprotein PTGDS Acts as a Potential Target in Diffuse Large B-Cell Lymphoma by regulating MYH9-Wnt-β-catenin/STAT3 axis.
Author: S.
Hu Unit: Shandong Provincial Hospital 09 Abstract Number: 256 Title: A Phase II Study of Anti-PD-1 Sintilimab in Combination With Chidamide and Azacitidine in Refractory and Relapsed Peripheral T-cell Lymphoma.
Author: Z.
Ying Unit: Peking University Cancer Hospital 10 Abstract Number: 269 Title: A single- arm, open-label, pilot trial of Autologous CD7-CAR-T Cells for CD7 Positive Relapsed and Refractory T-lymphoblastic leukemia/lymphoma.
Author: M.
Zhang Unit: The First Affiliated Hospital of Zhengzhou University 11 Abstract Number: 282 Title: Burden of lymphoma in China, 1990−2019: an analysis of Global Burden of Diseases, Injuries, and Risk Factors Study 2019.
Author: W.
Unit Liu: If there is any omission from Peking University Cancer Hospital, please leave us a message
.
